Savara (SVRA) Retained Earnings (2010 - 2026)
Savara (SVRA) reported Retained Earnings of -$429000.0 for Q1 2026, up 32.12% year-over-year from -$324704.2 in Q1 2025, and down 393.1% on a QoQ basis from -$87000.0 in Q4 2025.
Savara (SVRA) has 17 years of Retained Earnings data on file, last reported at -$429000.0 in Q1 2026.
- Quarterly Retained Earnings rose 32.12% year-over-year to -$429000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$429000.0 (up 32.12% YoY) and the FY2025 annual result came in at -$87000.0, up 88.4% from the prior year.
- Retained Earnings fell to -$429000.0 in Q1 2026 per SVRA's latest filing, from -$87000.0 in the prior quarter.
- Across five years, Retained Earnings topped out at -$87000.0 in Q4 2025 and bottomed at -$575.9 million in Q3 2025.
- The 5-year median for Retained Earnings is -$750000.0 (2024), against an average of -$178.3 million.
- The widest annual swing landed in 2022, when Retained Earnings plunged 115317.89%; it then surged 99.71% in 2023.
- Tracing SVRA's Retained Earnings over 5 years: stood at -$605000.0 in 2022, then surged by 55.21% to -$271000.0 in 2023, then plunged by 176.75% to -$750000.0 in 2024, then jumped by 88.4% to -$87000.0 in 2025, then sank by 393.1% to -$429000.0 in 2026.
- Per Business Quant, the three latest SVRA Retained Earnings figures stand at -$429000.0 (Q1 2026), -$87000.0 (Q4 2025), and -$575.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - | -429,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -429,000.00 |
| Dec 31, 2025 | -87,000.00 |
| Sep 30, 2025 | -575.85 Mn |
| Jun 30, 2025 | -546.30 Mn |
| Mar 31, 2025 | -632,000.00 |
| Dec 31, 2024 | -750,000.00 |
| Sep 30, 2024 | -460.21 Mn |
| Jun 30, 2024 | -435.96 Mn |
| Mar 31, 2024 | -742,000.00 |
| Dec 31, 2023 | -271,000.00 |
| Sep 30, 2023 | -942,000.00 |
| Jun 30, 2023 | -360.67 Mn |
| Mar 31, 2023 | -461,000.00 |
| Dec 31, 2022 | -605,000.00 |
| Sep 30, 2022 | -328.37 Mn |
| Jun 30, 2022 | -317.99 Mn |
| Mar 31, 2022 | -291,000.00 |
| Dec 31, 2021 | 5,000.00 |
| Sep 30, 2021 | 285,000.00 |
| Jun 30, 2021 | -278.67 Mn |
| Mar 31, 2021 | 485,000.00 |
| Dec 31, 2020 | -257.51 Mn |
| Sep 30, 2020 | -243.80 Mn |
| Jun 30, 2020 | -232.70 Mn |
| Mar 31, 2020 | -223.31 Mn |
| Dec 31, 2019 | -207.89 Mn |
| Sep 30, 2019 | -236,000.00 |
| Jun 30, 2019 | 212,000.00 |
| Mar 31, 2019 | 1,000.00 |
| Dec 31, 2018 | -129.72 Mn |
| Sep 30, 2018 | 364,000.00 |
| Jun 30, 2018 | 456,000.00 |
| Mar 31, 2018 | 1.28 Mn |
| Dec 31, 2017 | 958,000.00 |
| Sep 30, 2017 | -61.70 Mn |
| Jun 30, 2017 | 404,000.00 |
| Mar 31, 2017 | -316.94 Mn |
| Dec 31, 2016 | -591,000.00 |
| Sep 30, 2016 | -305.04 Mn |
| Jun 30, 2016 | -296.89 Mn |
| Mar 31, 2016 | 5,000.00 |
| Dec 31, 2015 | -17,000.00 |
| Sep 30, 2015 | 9,000.00 |
| Jun 30, 2015 | 9,000.00 |
| Mar 31, 2015 | -2,000.00 |
| Dec 31, 2014 | -235.13 Mn |
| Sep 30, 2014 | -22,521.00 |
| Jun 30, 2014 | -17,913.00 |
| Mar 31, 2014 | -26,185.00 |
| Dec 31, 2013 | -21,000.00 |
| Sep 30, 2013 | -28,722.00 |
| Jun 30, 2013 | 195.47 Mn |
| Mar 31, 2013 | 190.53 Mn |
| Dec 31, 2012 | -2,194.00 |
| Sep 30, 2012 | 180.95 Mn |
| Jun 30, 2012 | -2,295.00 |
| Mar 31, 2012 | -2,159.00 |
| Dec 31, 2011 | -2,298.00 |
| Sep 30, 2011 | -23,103.00 |
| Jun 30, 2011 | 163.48 Mn |
| Dec 31, 2010 | 156.13 Mn |